Article
The -374T/A variant of the rage gene promoter is associated with clinical restenosis after coronary stent placement.
International journal of immunopathology and pharmacology - 1 Jan 2000
Falcone C, Emanuele E, Buzzi M P, Ballerini L, Repetto A, Canosi U, Mazzucchelli I, Schirinzi S, Sbarsi I, Boiocchi C, Cuccia M
Abstract excerpt
Upregulation of the receptor for advanced glycation end products (RAGE) may play a crucial role in neointimal formation upon vessel injury. The -374T/A variant of the RAGE gene promoter, which has been associated with an altered expression of the cell-surface receptor, could exert a protective effect toward the development of vascular disease. The aim of this study is to determine the impact of this common...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.